Table 1.
Treatment | CD19+ B cells | Thy1.2+ T cells | Thymocytes | |||
---|---|---|---|---|---|---|
Wt | Ubi-junDm | Wt | Ubi-junDm | Wt | Ubi-junDm | |
UV (40 J/m2) | 75%±8 | 73%±5 | 50%±10 | 55%±9 | 62%±6 | 55%±9 |
TNF-α (10 ng/ml) | 35%±10 | 30%±8 | 52%±5 | 58%±7 | 55%±8 | 60%±6 |
anti-Fas (0.1 μg/ml) | n.d. | n.d. | n.d. | n.d. | 32%±5 | 30%±7 |
anti-CD3 (1 μg/ml) | n.d. | n.d. | 48%±7 | 51%±3 | 73%±9 | 74%±8 |
PMA/Iono | n.d | n.d. | 23%±0.9 | 23%±2 | n.d. | n.d. |
8- to 12-week-old wild-type and Ubi-junDm mice were used. Cells were stimulated for 24 h with the indicated death-promoting stimuli. Cell viability was determined in duplicate by AnnexinV and propidium iodide staining. The result of three independent experiments (±s.d.) is shown for each activation; n.d., not done. |